Author:
Bekele Raie T.,Venkatraman Ganesh,Liu Rong-Zong,Tang Xiaoyun,Mi Si,Benesch Matthew G. K.,Mackey John R.,Godbout Roseline,Curtis Jonathan M.,McMullen Todd P. W.,Brindley David N.
Publisher
Springer Science and Business Media LLC
Reference82 articles.
1. Jemal, A. et al. Cancer statistics, 2006. CA Cancer J Clin 56, 106–130, 10.3322/canjclin.56.2.106 (2006).
2. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351, 1451–1467, S0140673697114234 (1998).
3. Ring, A. & Dowsett, M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11, 643–658, 11/4/643 10.1677/erc.1.00776 (2004).
4. Jordan, V. C. Tamoxifen: a most unlikely pioneering medicine. Nature reviews. Drug discovery 2, 205–213, 10.1038/nrd1031 (2003).
5. Jaiyesimi, I. A., Buzdar, A. U., Decker, D. A. & Hortobagyi, G. N. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13, 513–529 (1995).
Cited by
103 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献